Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

BackgroundImmune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and compa...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2024-01, Vol.12 (1), p.e007823
Main Authors: Serafini, Mara Serena, Cavalieri, Stefano, Licitra, Lisa, Pistore, Federico, Lenoci, Deborah, Canevari, Silvana, Airoldi, Mario, Cossu Rocca, Maria, Strojan, Primoz, Kuhar, Cvetka Grasic, Merlano, Marco, Perrone, Federica, Vingiani, Andrea, Denaro, Nerina, Perri, Francesco, Argiris, Athanassios, Gurizzan, Cristina, Ghi, Maria Grazia, Cassano, Alessandra, Allegrini, Giacomo, Bossi, Paolo, De Cecco, Loris
Format: Article
Language:English
Subjects:
Anemia
Biomarkers
biomarkers, tumor
Cancer
Datasets
Head & neck cancer
head and neck neoplasms
Immunotherapy
Immunotherapy Biomarkers
Medical prognosis
Metastasis
Squamous cell carcinoma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundImmune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comparing the predictive role of gene-expression signatures with classical biomarkers for immunotherapy-treated R/M HNSCC patients in a multicentric phase IIIb trial.MethodsClinical data were prospectively collected in Nivactor tiral (single-arm, open-label, multicenter, phase IIIb clinical trial in platinum-refractory HNSCC treated with nivolumab). Findings were validated in an external independent cohort of immune-treated HNSCC patients, divided in long-term and short-term survivors (overall survival >18 and
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2023-007823